Blood-Brain Barrier Transport of 125I-Labeled Basic Fibroblast Growth Factor
Open accessThe DOI matches its Crossref record.
Abstract
AbstractPurpose. This study was carried out to examine the blood-brain barrier(BBB) transport of human basic fibroblast growth factor (bFGF) andinvestigate its mechanism. Methods. The BBB transport of 125I-bFGF was measured by severalin vivo methods including intravenous administration, in situ internalcarotid artery perfusion, and intracerebral microinjection. The in vitrobinding of 125I-bFGF was characterized using freshly prepared bovinebrain capillaries. Results. The distribution volume of 125I-bFGF in the postvascularsupernatant increased with the perfusion time, and exceeded the spaceoccupied by the brain microvasculature and its trichloroacetic acid(TCA) precipitability was more than 90%. 125I-bFGF avidly bound toisolated bovine brain capillaries with a Bmax of 206 ± 48 pmol/mgprotein, and a Kd of 36.5 ± 15.7 nM. This binding was significantlyinhibited by unlabeled bFGF and heparin in a concentration-dependentmanner. The cationic peptides, protamine and poly-L-lysine (each 300μM), produced over 85% inhibition of 125I-bFGF binding to braincapillaries. Furthermore, glycosaminoglycans with a sulfate residue,chondroitin sulfate B and C (each 10 μg/mL) also inhibited the bindingof 125I-bFGF. The in vivo transcytosis of 125I-bFGF from the luminalside to the brain was also inhibited by the presence of heparin (10μg/mL) and poly-L-lysine (300 μM), whereas neither hyaruronic acid (10μg/mL) nor insulin (10 μM) had any effect. In addition to these results,the brain efflux index method was used to confirm that the transcytosisof 125I-bFGF from brain to blood across the BBB was negligible. Conclusions. These results suggest that 125I-bFGF is transported acrossthe BBB, possibly by an adsorptive-mediated transcytosis mechanismthat is triggered by binding to negatively charged species on the luminalmembrane surface of the brain microvasculature, such as heparansulfate proteoglycans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Delivery of Neurotrophic Factors to the Central Nervous System: Pharmacokinetic Considerations
Thorne, R. G., & Frey, W. H. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140120-00003 · Cited by 487
Strategies to advance translational research into brain barriers
Neuwelt, E., Abbott, N. J., Abrey, L., Banks, W. A., Blakley, B., Davis, T., Engelhardt, B., Grammas, P., Nedergaard, M., Nutt, J., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70326-5 · Cited by 474
Self-citationSingewald, N., Schmuckermair, C., Whittle, N., Holmes, A., & Ressler, K. J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.004 · Cited by 390
“FGF2 has been shown to cross the blood–brain barrier (Deguchi et al., 2000) and pioneering work demonstrates that systemic administration of FGF2 prior to or following extinction training facilitates the consolidation of extinction memories (Graham & Richardson, 2009, 2010).”
BackgroundBrown, R. C., Morris, A. P., & O'Neil, R. G. (2007) · Brain Research · doi:10.1016/j.brainres.2006.10.083 · Cited by 291
Hippocampal FGF-2 and FGFR1 mRNA expression in major depression, schizophrenia and bipolar disorder
Gaughran, F., Payne, J., Sedgwick, P. M., Cotter, D., & Berry, M. (2006) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2006.04.008 · Cited by 178
Metadata
- Authors
- Deguchi, Y., Naito, T., Yuge, T., Furukawa, A., Yamada, S., Pardridge, W. M., & Kimura, R.
- Venue
- Pharmaceutical Research
- Published
- 2000-01
- Volume
- 17
- Issue
- 1
- Pages
- 63-69
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W1534316263
- Cited by
- 68
- References
- 0
- FWCI
- 2.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Blood-Brain Barrier Transport of 125I-Labeled Basic Fibroblast Growth Factor. https://app.cochat.ai/papers/10.1023/a:1007570509232
- The paper
- Deguchi, Y., Naito, T., Yuge, T., Furukawa, A., Yamada, S., Pardridge, W. M., & Kimura, R. (2000). Blood-Brain Barrier Transport of 125I-Labeled Basic Fibroblast Growth Factor. Pharmaceutical Research. https://doi.org/10.1023/a%3A1007570509232
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.